| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Lisa McClain MI09 | 1 | 1 | +$0 | Sold Jul 22, 25 |
| Rob Bresnahan PA08 | 1 | 1 | +$0 | Sold Apr 8, 25 |
| Jared Moskowitz FL23 | 1 | −$8.0K | Sold Feb 13, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Jul 22, 25 | Lisa McClain MI09 | Spouse | Sell | $1,001 - $15,000 | Aug 13, 25 (22d) | |
| Jun 17, 25 | Lisa McClain MI09 | Spouse | Buy | $1,001 - $15,000 | Aug 13, 25 (57d) | |
| Apr 8, 25 | Rob Bresnahan PA08 | Self | Sell | $1,001 - $15,000 | May 8, 25 (30d) | |
| Feb 25, 25 | Rob Bresnahan PA08 | Self | Buy | $1,001 - $15,000 | Mar 27, 25 (30d) | |
| Feb 13, 25 | Jared Moskowitz FL23 | Child | Sell | $1,001 - $15,000 | Mar 6, 25 (21d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Favorite Annette FOfficer | Sale at price 345.00 - 365.00 per share. | 7.5K | $2.67M |
| Sep 14, 2026 | Favorite Annette FOfficer | Conversion of Exercise of derivative security at price 89.64 per share. | 7.5K | $674.45K |
| Sep 7, 2026 | Favorite Annette FOfficer | Sale at price 340.81 per share. | 8.1K | $2.77M |
| Sep 7, 2026 | Favorite Annette FOfficer | Conversion of Exercise of derivative security at price 83.47 - 89.64 per share. | 8.1K | $694.45K |
| Aug 10, 2026 | Mcmahon Robert WChief Financial Officer | — | 7.1K | — |
| May 11, 2026 | Campbell Shane AldenOfficer | — | 769 | — |
| May 3, 2026 | Buthman Mark ADirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Michels Douglas ADirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Lai-Goldman Myla PDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Friel Robert FDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Haugen Janet BrutscheaDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Feehery William F.Director | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Pucci PaoloDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Keller Deborah LDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Joseph Molly E.Director | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| May 3, 2026 | Lockhart Stephen HDirector | Stock Award(Grant) at price 0.00 per share. | 791 | — |
| Apr 26, 2026 | Favorite Annette FOfficer | Sale at price 305.20 per share. | 2.8K | $859.75K |
| Apr 26, 2026 | Winters ChadOfficer | Sale at price 300.67 per share. | 896 | $269.40K |
| Apr 26, 2026 | Favorite Annette FOfficer | Conversion of Exercise of derivative security at price 83.47 per share. | 2.8K | $235.13K |
| Apr 26, 2026 | Winters ChadOfficer | Conversion of Exercise of derivative security at price 173.22 per share. | 896 | $155.21K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.0 | 10.0 | -1.5 | 18.7 | 8.5 | 11.2 | -5.0 | 0.0 | 8.7 | -0.9 | +33.6% | ||
| 2025 | 4.3 | -32.0 | -3.6 | -5.6 | -0.2 | 3.8 | 9.4 | 3.2 | 6.2 | 7.5 | -1.7 | -0.8 | −16.0% |
| 2024 | 5.9 | -3.9 | 10.4 | -9.7 | -7.3 | -0.6 | -7.0 | 2.4 | -4.3 | 2.6 | 5.8 | 0.6 | −7.0% |
| 2023 | 12.9 | 19.4 | 9.3 | 4.3 | -7.4 | 14.3 | -3.8 | 10.6 | -7.8 | -15.2 | 10.2 | 0.4 | +49.6% |
| 2022 | -16.2 | -1.6 | 6.1 | -23.3 | -1.5 | -2.6 | 13.6 | -13.6 | -17.1 | -6.5 | 2.0 | 0.3 | −49.8% |
| 2021 | 5.7 | -6.3 | 0.4 | 16.6 | 5.8 | 3.3 | 14.7 | 9.7 | -6.0 | 1.3 | 3.0 | 6.0 | +65.5% |
| 2020 | 3.7 | -3.5 | 1.1 | 24.3 | 14.1 | 5.2 | 18.4 | 5.6 | -3.2 | -1.0 | 1.1 | 3.0 | +88.5% |
| 2019 | 10.4 | -3.3 | 5.2 | 12.3 | -7.4 | 9.2 | 9.7 | 6.0 | -2.5 | 1.4 | 2.2 | 2.2 | +53.4% |
| 2018 | 1.6 | -13.0 | 1.2 | -0.1 | 5.4 | 6.8 | 10.4 | 6.7 | 5.5 | -14.2 | 3.4 | -10.5 | −0.6% |
| 2017 | -0.2 | -2.6 | -1.0 | 12.8 | 5.4 | -2.6 | -6.2 | -1.9 | 10.6 | 5.3 | -1.4 | -1.3 | +16.3% |
| 2016 | -5.0 | 8.4 | 11.8 | 2.7 | 5.4 | 1.1 | 5.8 | 1.9 | -9.0 | 2.1 | 6.7 | 4.5 | +40.9% |
| 2015 | -7.4 | 11.0 | 10.0 | -11.5 | 1.6 | 7.3 | 3.1 | -6.7 | -3.1 | 10.9 | 5.1 | -4.5 | +13.1% |
| 2014 | -3.3 | -3.9 | -3.4 | -1.5 | -3.0 | 0.2 | -3.4 | 6.6 | 3.1 | 14.5 | 1.5 | 2.4 | +8.5% |
| 2013 | 8.1 | 2.0 | 7.5 | -1.7 | 7.3 | 2.5 | 5.0 | 0.3 | 11.3 | 17.5 | 3.2 | -1.7 | +79.2% |
| 2012 | 6.7 | 2.8 | 2.2 | 5.6 | 6.5 | 5.6 | -1.4 | -4.9 | 12.1 | 1.5 | 0.3 | 1.3 | +44.3% |
| 2011 | -2.9 | 2.8 | 8.9 | 5.5 | -1.6 | -5.9 | 0.3 | -8.5 | -7.5 | 4.8 | -0.9 | -1.5 | −7.9% |
| 2010 | -7.3 | 7.2 | 7.7 | -0.2 | -6.0 | -7.3 | -0.4 | -7.5 | 2.1 | 4.0 | 6.2 | 8.6 | +5.1% |
| 2009 | -12.0 | -7.6 | 6.9 | -0.5 | -1.0 | 7.8 | 4.7 | 10.1 | 1.0 | -2.8 | -2.3 | 1.7 | +3.8% |
| 2008 | -3.7 | 5.6 | 7.1 | 6.1 | 1.1 | -8.7 | 6.1 | 6.3 | 0.0 | -18.2 | -11.1 | 6.4 | −6.9% |
| 2007 | -5.3 | -6.7 | 2.6 | 7.2 | 2.2 | -7.3 | -1.8 | -13.5 | 4.0 | -0.8 | -9.1 | 8.0 | −20.8% |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Buy / hold / sell counts